Marcel Rozencweig, Md
Executive Vice President and Chairman of Innate Ph
immunology
pharma
Ghana
Biography
Dr. Rozencweig joined Innate Pharma in 2009. He is recognized as a world leading expert and opinion leader in medical oncology and anti-cancer drug development. He built and led the clinical research group at Bristol-Myers Squibb (“BMS”) that developed all the NCEs brought by BMS to the market from 1983 to 2001 in the area of cancer (including carboplatin and paclitaxel).
Research Interest
Before joining the industry, Dr. Rozencweig pursued an academic career and currently serves as an Adjunct Associate Professor of Medicine at New York University, NY. He created and chaired a number of European groups (EORTC) devoted to multinational drug-oriented and disease-oriented trials (e.g., Early Clinical Trials Group).
